ACQ-5 and AQLQ(S) in adults (≥18 years) and adolescents (12–17 years): results from QUEST at 52 weeks1

Table showing the ACQ-5 responder rate, which was a secondary endpoint. The rates for DUPIXENT 200 mg every two weeks and placebo 69% and 62%, respectively. The rates for DUPIXENT 300 mg every two weeks and placebo were 69% and 63%, respectively. Please note that the table title is cross referenced to a footnote that states, “Responder rate was defined as an improvement in score of at least 0.5 units for ACQ-5 (scale range 0 to 6) and AQLQ(s) (scale range 1 to 7), respectively. Table showing the AQLQ(S) responder rate, which was a secondary endpoint. The rates for DUPIXENT 200 mg every two weeks and placebo 62% and 54%, respectively. The rates for DUPIXENT 300 mg every two weeks and placebo were 62% and 57%, respectively. Please note that the table title is cross referenced to a footnote that states, “Responder rate was defined as an improvement in score of at least 0.5 units for ACQ-5 (scale range 0 to 6) and AQLQ(s) (scale range 1 to 7), respectively.

The ACQ-5 and AQLQ(S) responder rates in subjects with baseline blood eosinophils ≥300 cells/mcL were consistent with the overall population.
Asthma Control Questionnaire, or ACQ-5, is a patient-reported measure of the adequacy of asthma control and change in asthma control that occurs either spontaneously or as a result of treatment.4 
Asthma Quality of Life Questionnaire Standardized Version, or AQLQ(S), is a patient-reported measure of the impact of asthma on quality of life.4

* Responder rate was defined as an improvement in score of at least 0.5 units for ACQ-5 (scale range 0-6) and AQLQ(s) (scale range 1-7), respectively.

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.

Freedom support program logo.

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients and how you can help them access it.


Sanofi Regeneron Logo

DUPIXENT® (dupilumab injection) logo


DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300228
Last updated: 06/2023


Innovative Medicines Canada logo PAAB logo